An observational study in Chronic Heart Failure, sponsored by AstraZeneca. Completed at 15 sites in Croatia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-07.
Sponsored by AstraZeneca · Observational
The purpose of this study is to determine whether treatment with candesartan cilexetil for at least 6 months in patients with chronic heart failure improves clinical signs and symptoms of chronic heart failure.
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →AstraZeneca is the lead sponsor of 3,429 studies on the registry; 270 are open to participants now.
Of its 357 completed or terminated interventional studies of FDA-regulated products, 173 (48%) have results posted.
Counted across the registry records on this site, refreshed daily.
Primary Care
Exclusion Criteria:
Cardiologist´s office patients
To evaluate clinical signs and symptoms of chronic heart failure (in terms of NYHA status, fluid retention and tiredness/fatigue) after at least 6 months of treatment with candesartan cilexetil
Time frame: 1 visit (after at least 6 months of treatment)
To evaluate ventricular function after at least 6 months of treatment with candesartan cilexetil
Time frame: 1 visit (after at least 6 months of treatment)
To gain insight into usage of candesartan cilexetil in real life for chronic heart failure in Croatia
Time frame: 1 visit (after at least 6 months of treatment)
To evaluate patient's compliance with prescribed treatment
Time frame: 1 visit (after at least 6 months of treatment)
This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AstraZeneca